RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages

  Gupta, Nikhil ^a   Dasyam, Anil K ^c   Carty, Sally E ^b   Nikiforova, Marina N ^a   Ohori, N Paul ^a   Armstrong, Michaele ^b   Yip, Linwah ^b   LeBeau, Shane O ^a   McCoy, Kelly L ^b   Coyne, Christopher ^a   Stang, Michael T ^b   Johnson, Jonas ^c   Ferris, Robert L ^c   Seethala, R ^a   Nikiforov, Yuri E ^a   Hodak, Steven P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Division of Endocrine Surgery   (United States)

^c Department of Radiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN; THYROGLOBULIN;

ADULT; ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID CANCER; ARTICLE; BILATERAL CANCER; BONE METASTASIS; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CYTOLOGY; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; ECHOGRAPHY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LOBECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; NECK DISSECTION; ONCOGENE RAS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; BIOPSY, FINE-NEEDLE; COHORT STUDIES; FAMILY HEALTH; FEMALE; FOLLOW-UP STUDIES; GENES, RAS; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; THYROID GLAND; THYROID NEOPLASMS; TUMOR BURDEN; YOUNG ADULT;

EID: 84877713299     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3396     Document Type: Article

References (38)

1. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553-559.
2. Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract. 2010;16:468-475.
3. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;111:508-516.
4. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
5. Cantara S, Capezzone M, Marchisotta S, et al. Impact of protooncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95:1365-1369.
6. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance." Cancer Cytopathol. 2010;118:17-23.
7. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-3397.
8. Fagin JA. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol. 2002;16:903-911.
9. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Modern Pathology. 2008;2(suppl 21):S37-S43.
10. Fehrenbacher N, Bar-Sagi D, Philips M. Ras/MAPK signaling from endomembranes. Mol Oncol. 2009;3:297-307.
11. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9:517-531.
12. Moon A. Differential functions of Ras for malignant phenotypic conversion. Arch Pharmacal Res. 2006;29:113-122.
13. Kyriakis JM. Thinking outside the box about Ras. J Biol Chem. 2009;284:10993-10994.
14. Poghosyan Z, Wynford-Thomas D. Analysis of Ras transformation of human thyroid epithelial cells. Methods Enzymol. 2006;407: 648-660.
15. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol. 1990;4: 1474-1479.
16. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88:2745-2752.
17. Stang MT, Armstrong MJ, Ogilvie JB, et al. Positional dyspnea and tracheal compression as indications for goiter resection. Arch Surg. 2012;147(7):621-626.
18. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19: 1167-1214.
19. McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH. The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery. 2007;142: 837-844; discussion 844.e831-e833.
20. Cooper DS, Doherty GM, Haugen BR, et al. Managementguidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
21. Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology. New York: Springer; 2010.
22. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
23. Ozdemir D, Ersoy R, Cuhaci N, et al. Classical and follicular variant papillary thyroid carcinoma: comparison of clinical, ultrasonographical, cytological, and histopathological features in 444 patients. Endocr Pathol. 2011;22:58-65.
24. Iared W, Shigueoka DC, Cristofoli JC, et al. Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis. J Ultrasound Med. 2010;29:419-425.
25. Yoon JH, Kim EK, Hong SW, Kwak JY, Kim MJ. Sonographic features of the follicular variant of papillary thyroid carcinoma. J Ultrasound Med. 2008;27:1431-1437.
26. Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736-744.
27. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28:1336-1340.
28. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120:71-77.
29. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.
30. Nikiforov YE, Ohori NP. Follicular adenoma. In: Nikiforov YE, Biddinger PW, Thompson LDR eds. Diagnostic Pathology and Molecular Genetics of the Thyroid: A Comprehensive Guide for Practicing Thyroid Pathology. 2nd ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2012;119-142.
31. Burns JS, Blaydes JP, Wright PA, et al. Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression. Mol Carcinog. 1992;6:129-139.
32. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569-580.
33. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17-44.
34. Johnston D, Hatzis D, Sunday ME. Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma. Oncogene. 1998;16:167-177.
35. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:E863-E868.
36. De Nicola H, Szejnfeld J, et al. Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasms. J Ultrasound Med. 2005;24:897-904.
37. Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006;107:1255-1264.
38. Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010;23:1191-1200.